Clinical Trials
10 trialsNCT03112603 2025-08-12
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
Phase 3 Completed
NCT00577278 2024-02-16
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
City of Hope Medical Center
Phase 2 Completed
NCT01044745 2023-09-06
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
University of Nebraska
Phase 2 Terminated
NCT02423915 2021-01-08
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00785330 2020-01-13
Allo-hNHL (FluBuCy)
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Phase 2 Completed
NCT01116232 2019-03-26
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT02484053 2018-07-11
Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders
Baylor College of Medicine
Phase EARLY_PHASE1 Completed
NCT01810926 2013-03-14
T&B Depletion Non Malignant
Bambino Gesù Hospital and Research Institute
Phase 2 Unknown
NCT00427557 2012-05-28
Cellular Therapy With Cord Blood Cells
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00473551 2011-12-19
Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated